Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data
Digestive and Liver Disease · 2026
DOI: 10.1016/j.dld.2025.09.026 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Digestive and Liver Disease, 2026. Verfasst von Laurent Peyrin-Biroulet und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nancy University Hospital, Vandœuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson Innovative Medicine.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nancy University Hospital, Vandœuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com.
- Janssen-Cilag Polska Sp. z o.o., Warsaw, Poland. Electronic address: mnazar1@its.jnj.com.
- Global Epidemiology, Janssen Research and Development, LLC, Spring House, PA, USA. Electronic address: ASheaha1@ITS.JNJ.com.
- Medical Affairs, Janssen Biologics B.V., Leiden, Netherlands. Electronic address: ageldho1@its.jnj.com.
- EMEA Medical Affairs, Johnson & Johnson, Casablanca Finance City, Morocco. Electronic address: aazzabi@ITS.JNJ.com.
- Department of Gastroenterology, AZ Delta, Rumbeke, Belgium. Electronic address: filip.baert@azdelta.be.
Förderung
- Johnson & Johnson Innovative Medicine
Zitieren
APA
Peyrin-Biroulet, L., Nazar, M., Sheahan, A., Geldhof, A., Azzabi, A., Baert, F., Mailhat, C., Rousseau, H., Rahier, J. F., & Beaugerie, L. (2026). Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.09.026
Vancouver
Peyrin-Biroulet L, Nazar M, Sheahan A, Geldhof A, Azzabi A, Baert F, et al. Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data. Digestive and Liver Disease. 2026. doi:10.1016/j.dld.2025.09.026
BibTeX
@article{PeyrinBiroulet2026,
author = {Peyrin-Biroulet, Laurent and Nazar, Maciej and Sheahan, Anna and Geldhof, Anja and Azzabi, Ahlem and Baert, Filip and Mailhat, Charlotte and Rousseau, Hélène and Rahier, Jean-François and Beaugerie, Laurent},
title = {Long-term safety of ustekinumab in Crohn’s disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data},
journal = {Digestive and Liver Disease},
year = {2026},
doi = {10.1016/j.dld.2025.09.026}
}
EUVIMED